Clinical Trials
53
Active:0
Completed:49
Trial Phases
4 Phases
Phase 1:18
Phase 2:8
Phase 3:22
+1 more phases
Drug Approvals
5
NMPA:4
PHILIPPINES:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials
Phase 3
22 (41.5%)Phase 1
18 (34.0%)Phase 2
8 (15.1%)Phase 4
5 (9.4%)Efficacy and Safety of SKCPT in Patients With Knee Osteoarthritis: Phase III Clinical Trial
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 278
- Registration Number
- NCT05930080
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy.
Phase 4
Completed
- Conditions
- Diabetic Peripheral Angiopathy
- Interventions
- Drug: Renexin CR 200/160mg
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT05906199
- Locations
- 🇰🇷
SKChemicals, Seongnam, Gyunggi-do, Korea, Republic of
🇰🇷SK chemicals, Seoul, Korea, Republic of
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT05453786
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT05445895
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Clinical Trial for GNX80 in Intermittent Claudication
Phase 4
Recruiting
- Conditions
- Intermittent Claudication
- Interventions
- Drug: GNX80Drug: Placebo
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05400395
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found